Vion Pharmaceuticals Inc (VION) financial news, and detailed stock charts
This company symbol is outdated. Results displayed are archieved for your information
Vion Pharmaceuticals Inc (VION) Stock Summary:
Vion Pharmaceuticals, Inc., a development-stage pharmaceutical company, develops and commercializes therapeutics for the treatment of cancer. It has two agents in clinical trials, Onrigin and Triapine. Onrigin, a novel alkylating agent that damages DNA to prevent cancer cells from reproducing, is in various clinical trials for the treatment of various indications, such as acute myeloid leukemia (AML), relapsed AML, de novo poor-risk, small cell lung cancer, brain tumors, myelodysplastic syndromes, chronic lymphocytic leukemia, hematologic malignancies, and solid tumors. Triapine is a small molecule in various clinical trials to prevent the replication of tumor cells by blocking a critical step in DNA synthesis. The company?s other products and product candidates include MELASYN, a water-soluble, synthetic version of melanin for formulation of skin care products and cosmetics; and Nucleoside Analogs, known as elvucitabine, which is in Phase II clinical trials as an antiviral drug for the treatment of human immunodeficiency virus. Vion Pharmaceuticals has licensing and research agreement with Yale University. The company was formerly known as OncoRx, Inc. and changed its name to Vion Pharmaceuticals, Inc. in April 1996. Vion Pharmaceuticals was founded in 1992 and is based in New Haven, Connecticut. On December 17, 2009, Vion Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Archieved Financial News About Vion Pharmaceuticals Inc
Vion Pharmaceuticals Files for Chapter 11 Bankruptcy
2009-12-23 03:56:52
Quote: 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION), a pharmaceutical company focused on the development of novel cancer therapeutics, announced that it had voluntarily filed for bankruptcy under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Â Vion is continuing to operate its business as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code."We believe that the Chapt...Read article
VION PHARMACEUTICALS INC Files SEC form 8-K, Other Events
2009-12-23 03:56:52
Quote: Item 8.01 Other Events.
On December 14, 2009, Vion Pharmaceuticals, Inc. (the "Company") issued a press
release announcing that it had received a complete response letter from the U.S.
Food and Drug Administration ("FDA") related to its New Drug Application ("NDA")
for Onrigin™ (laromustine) injection submitted in February 2009. The letter
indicated that the FDA cannot approve the Company's NDA in its present form and
provided recommendations to address remainin...Read article
VION PHARMACEUTICALS INC Files SEC form 8-K, Bankruptcy or Receivership
2009-12-23 03:56:51
Quote: Item 1.03 Bankruptcy and Receivership
On December 17, 2009, Vion Pharmaceuticals, Inc. (the "Debtor" or the "Company")
filed a voluntary petition (the "Chapter 11 Petition") for relief under
Chapter 11 of Title 11 of the United States Bankruptcy Code (the "Bankruptcy
Code") in the United States Bankruptcy Court for the District of Delaware (the
"Bankruptcy Court").
Under Chapter 11, certain claims in existence prior to the Debtor's filing of
t...Read article
InPlay: Vion Pharma receives Complete Response Letter; engages Roth Capital Partners for assistance with evaluating strategic alternatives
2009-12-15 01:21:37
Quote: Read article
Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
2009-12-15 01:21:37
Quote: 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that it had received a complete response letter from the U.S. Food and Drug Administration ("FDA") related to its New Drug Application ("NDA") for Onriginâ„¢ (laromustine) injection submitted in February 2009. Â The letter indicates that the FDA cannot approve the Company's NDA in its present form and provides recommendations to address remaining issues.Alan Kessman, Chief Executive Officer, ...Read article
Vion Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference
2009-11-30 01:26:36
Quote: 9 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. VIONNews) today announced that it would make a corporate presentation at the 11th Annual Rodman & Renshaw Healthcare Conference in New York City.The presentation will be on Thursday, September 10, 2009 at 5:45 p.m. in the Hubbard Salon, 5th Floor, of the New York Palace Hotel.www.vionpharm.com, at the time of the presentation.About Vion Pharmaceuticalsde novowww.vionpharm.com.This news release contains forward-looking statements. Such st...Read article
Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
2009-11-30 01:26:35
Quote: 12 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. VIONNews) announced today that it had hired the investment banking firm Merriman Curhan Ford & Co. to assist in evaluating its strategic alternatives. These alternatives include any combination of a restructuring of the Company and its debt and a sale of the Company or its assets. The Company may also consider financing options.de novo poor-risk acute myeloid leukemia (AML). As Vion would need to raise additional capital to finance a ne...Read article
Skymark Research Initiates Independent Research Coverage On Vion Pharmaceuticals, Inc.
2009-11-30 01:26:35
Quote: To view our research reports on a complimentary trial basis and take advantage of our other services, go toand click on the complimentary trial subscription button on our home page, or go directly to our registration page atAbout Vion Pharmaceuticals, Inc.(OTCBB: -Vion Pharmaceuticals, Inc.(OTCBB: - ) is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinica...Read article
VION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
2009-11-30 01:26:35
Quote: VION PHARMACEUTICALS INCRequest a Trial to NEW EDGAR Online Pro
Form
8-K for
VION PHARMACEUTICALS INC
9-Sep-2009Change in Directors or Principal OfficersPrivacy PolicyTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors, incom...Read article
Vion Pharmaceuticals Reports 2009 Third Quarter and Nine-Month Results
2009-11-30 01:26:34
Quote: 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. VIONNews) today announced financial results for the three-month and nine-month periods ending September 30, 2009.For the third quarter of 2009, the Company reported a net loss of $6.2 million, or $0.78 per share, compared with a net loss of $6.8 million, or $0.92 per share, for the same 2008 period.Weighted-average common shares outstanding for the three-month periods ended September 30, 2009 and 2008 were 8.0 million and 7.4 million, respe...Read article
VION PHARMACEUTICALS INC Files SEC form 8-K, Other Events
2009-11-30 01:26:34
Quote: Item 8.01 Other Events.
On October 12, 2009, Vion Pharmaceuticals, Inc. (the "Company") issued a press
release announcing that it had hired the investment banking firm Merriman Curhan
Ford & Co. to assist in evaluating its strategic alternatives. These
alternatives include any combination of a restructuring of the Company and its
debt and a sale of the Company or its assets. The Company may also consider
financing options. If the Company is unsuccessful in achieving a restructuri...Read article
VION PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
2009-11-30 01:26:33
Quote: Read article
VION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
2009-11-30 01:26:33
Quote: Item 2.02.Results of Operations and Financial Condition.
On November 10, 2009, Vion Pharmaceuticals, Inc. (the "Company") issued a
press release reporting its financial results for the third quarter and nine
month period ended September 30, 2009. A copy of that press release is attached
hereto as Exhibit 99.1 and is furnished solely for the purposes of this
Item 2.02.
On November 12, 2009, the Company held a conference call to discuss its
financial results for the third quarter ende...Read article
Vion Pharmaceuticals Earnings Call scheduled for 8:30 am ET today
2009-11-30 01:26:33
Quote: Call DetailsVion Pharmaceuticals Earnings Conference Call (Q3 2009)Thu,
Nov 12, 2009, 8:30 am EasternAbout Vion PharmaceuticalsVION.OB)Vion Pharmaceuticals, Inc., a development-stage pharmaceutical company, develops and commercializes therapeutics for the treatment of cancer. It has two agents in clinical trials, Onrigin and Triapine. Onrigin, a novel alkylating agent that damages DNA to prevent cancer cells from reproducing, is in various clinical trials for the treatment of various indications...Read article
You can still leave a comment about Vion Pharmaceuticals Inc VION
Besides Vion Pharmaceuticals Inc's Stock there is more great Microcap and Stock Market information available at Realpennies.com